Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Pharmalot
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Zogenix drug cuts seizure rate in severe epilepsy, sending stock skyrocketing

  • Adam Feuerstein

By Adam Feuerstein Sept. 29, 2017

Reprints

Zogenix (ZGNX) closed out September’s crammed clinical trial calendar with an impressive win.

The small biotech company, based in Emeryville, Calif., said its lead drug, ZX008, significantly reduced seizure activity compared to a placebo in children with Dravet syndrome, a rare and severe type of epilepsy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Researchers devise new strategies to overcome a key CRISPR…
Researchers devise new strategies to overcome a key CRISPR flaw
Human reproductive cloning: The curious incident of the dog…
Human reproductive cloning: The curious incident of the dog in the night-time
Why your doctor’s advice to take all your antibiotics…
Why your doctor’s advice to take all your antibiotics may be wrong
J&J loses a patent battle in India over a…
J&J loses a patent battle in India over a crucial tuberculosis drug
Pharmalittle: FDA panel backs conditional approval for Biogen ALS…
Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs

Recommended Stories